Dr. Reddy’s Laboratories announced today that it has launched Levalbuterol Inhalation Solution in multiple dosage vials in the US market on Tuesday.
It is a therapeutic equivalent generic version of XOPENEX (levalbuterol hydrochloride) inhalation solution and approved by the United States Food & Drug Administration (USFDA). The dosages are USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg / 3 mL Unit-Dose Vials.
The Xopenex inhalation solution brand and generic combined had U.S. sales of approximately $269.7 Million MAT for the most recent twelve months ending in June 2014 according to IMS Health.
Dr. Reddy’s Levalbuterol Inhalation Solution are in Unit-Dose Vials of (5 x 3 mL) carton of 25. Levalbuterol Inhalation Solution, USP is only for use with a nebulizer, a company release said.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.